| 摘要 |
<p>PURPOSE: A trans-splicing enzymatic nucleic acid molecule specific to splicing variant of aimp2 gene is provided to be used for lung cancer treatment, as a diagnostic material which diagnose progression of lung cancer and as an in-vivo imaging reagent. CONSTITUTION: A vector includes a promoter; a ribozyme domain which codes trans-splicing ribozyme which operates specific to AIMP2-DX2 transfer body; and therapy genes connected to 3' of the ribozyme domain or reporter genes in the order from 5' to 3'. The AIMP2-DX2 transfer body is splicing variant of the AIMP2 (Aminoacyl-tRNA synthetase Interacting Multifunctional Protein 2) gene in which Exxon 2 is lost. The ribozyme includes inside guide sequence (IGS) of the sequence number 1 or 2. The pharmaceutical composition for lung cancer includes the vector as the active ingredient. The pharmaceutical composition is in an absorption formulation form. The composition for lung cancer diagnosis includes the vector as the active ingredient. [Reference numerals] (3') Exxon (HSVtk); (AA) AIMP2-whole length; (BB,II) Exxon 1; (CC) Exxon 2; (DD,JJ) Exxon 3; (EE,KK) Exxon 4; (FF) AIMP2-DX2 (splicing variant AIMP2); (GG) AIMP2-DX2 RNA (splicing variant AIMP2); (HH) Trans- splicing ribozyme including treatment RNA; (LL) Target area; (MM) Ribozyme; (NN) Flaw in substrate RNA (connection point of Exxon 1 - Exxon 3) ;; (OO) Cut target RNA ;; (PP) Connect treatment RNA ;; (QQ) Express treatment RNA</p> |
